基于IRS/PI3K/AKT通路的GABA丰富的阿兹基豆调节血糖的机制研究
Xiujie Jiang1,2, Ying Li1, Zhenzhen Cao1
1College of Food Science, Heilongjiang Bayi Agricultural University, Daqing 163319, China.
Foods (Basel, Switzerland)
|September 14, 2024
概括
富含GABA的阿祖基豆通过激活IRS/PI3K/AKT通路来改善2型糖尿病小鼠的高血糖. 这种饮食干预促进了糖原合成,并调节了肝脏中的脂质代谢.
科学领域:
- 生物化学 生物化学
- 代谢障碍 代谢障碍 代谢障碍
- 营养科学 营养科学
背景情况:
- 阿祖基豆是一种营养丰富的豆类,因其氨基酸特征而受到重视.
- 发芽增强了阿兹基豆,特别是通过胺酸 (GABA) 丰富,改善了健康益处.
- 2型糖尿病 (T2DM) 的特点是葡萄糖和脂质代谢受损.
研究的目的:
- 为了研究GABA丰富的阿祖基豆消费对T2DM小鼠肝脏中胰岛素相关基因和蛋白质表达的影响.
- 阐明GABA丰富的阿祖基豆对T2DM中的葡萄糖和脂质代谢产生影响的分子机制.
主要方法:
- 使用定量实时PCR (qPCR) 来分析基因表达水平.
- 西方涂抹被用于评估蛋白质表达和酸化.
- 这项研究使用了2型糖尿病 (T2DM) 的小鼠模型.
主要成果:
- 富含GABA的阿祖基豆促进了肝脏的糖原合成,并抑制了参与葡萄糖生产的关键酶 (PEPCK,G-6-Pase).
- *PEPCK*, *G6PC* 和 *FOXO1* 的基因表达显著下调,同时减少了FOXO1和GSK3β的酸化.
- 饮食干预上调*AMPKα*和下调*SREBP1c*,抑制肝脏甘油三和胆固醇合成,从而缓解脂质积累和代谢障碍.
结论:
- 富含GABA的阿祖基豆有效地改善T2DM小鼠的高血糖症.
- 这些有益的效果是通过激活肝脏中的IRS/PI3K/AKT信号通路来实现的.
- 这表明GABA丰富的阿祖基豆在治疗2型糖尿病方面具有潜在的治疗作用.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
178
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
178
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.2K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.2K
Insulin: The Receptor and Signaling Pathways
1.2K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.2K
Hormones Regulating Blood Glucose
3.1K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.1K
cAMP-dependent Protein Kinase Pathways
6.2K
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
6.2K
Glucagon-like Receptor Agonists
306
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
306


